Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tole
- This topic has 0 replies, 1 voice, and was last updated 5 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors.
http://abstracts.asco.org/239/AbstView_239_267875.html
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.